Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Letter to the editor: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus

Letter to the editor: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent... 0 1992 Wiley-Liss, Inc. etiological agent of erythema infectiousurn but it is also known as a cause of arthropaty, febrile illness, aplastic crisis, and recently also thrombocytopenia [2]. Persistent B 19 infection may occur in immunodeficient patients, leading to chronic anemia 13-51. The seroconversion for B 19 virus develops between 5 and 7 years of life in about 30% of normal children and a similar prevalence of IgG specific for B19 has been observed in blood donors [6]. Viremia has been observed in only 1 out of 10,000 normal people. Because of the very large number of blood donors (up to 20,00030,000) participating in the plasma pool for industrial fractionation, clotting factor concentrates are at high risk of transmitting B19 virus to the recipients. The prevalence of B19-IgG in hemophiliacs infused before 1985 with concentrates not subjected to virucidal methods is very high: 90-95% [6,7]. Furthermore, B19 is very resistant to virucidal methods developed so far: seroconversion against B 19 has been detected in previously untreated hemophilic patients after the first treatment with dry-, wet-, and steam-heated factor VIII concentrates [6,8]. It is well known that the solventldetergent method destroys only the lipid-enveloped viruses. B 19 virus has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Hematology Wiley

Letter to the editor: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus

Loading next page...
 
/lp/wiley/letter-to-the-editor-hypoplastic-anemia-in-a-hemophiliac-first-infused-LC4FE8X770

References (9)

Publisher
Wiley
Copyright
Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company
ISSN
0361-8609
eISSN
1096-8652
DOI
10.1002/ajh.2830390217
Publisher site
See Article on Publisher Site

Abstract

0 1992 Wiley-Liss, Inc. etiological agent of erythema infectiousurn but it is also known as a cause of arthropaty, febrile illness, aplastic crisis, and recently also thrombocytopenia [2]. Persistent B 19 infection may occur in immunodeficient patients, leading to chronic anemia 13-51. The seroconversion for B 19 virus develops between 5 and 7 years of life in about 30% of normal children and a similar prevalence of IgG specific for B19 has been observed in blood donors [6]. Viremia has been observed in only 1 out of 10,000 normal people. Because of the very large number of blood donors (up to 20,00030,000) participating in the plasma pool for industrial fractionation, clotting factor concentrates are at high risk of transmitting B19 virus to the recipients. The prevalence of B19-IgG in hemophiliacs infused before 1985 with concentrates not subjected to virucidal methods is very high: 90-95% [6,7]. Furthermore, B19 is very resistant to virucidal methods developed so far: seroconversion against B 19 has been detected in previously untreated hemophilic patients after the first treatment with dry-, wet-, and steam-heated factor VIII concentrates [6,8]. It is well known that the solventldetergent method destroys only the lipid-enveloped viruses. B 19 virus has

Journal

American Journal of HematologyWiley

Published: Feb 1, 1992

There are no references for this article.